Annual CFO
-$89.23 M
-$13.97 M-18.56%
30 April 2024
Summary:
KalVista Pharmaceuticals annual cash flow from operations is currently -$89.23 million, with the most recent change of -$13.97 million (-18.56%) on 30 April 2024. During the last 3 years, it has fallen by -$59.06 million (-195.75%). KALV annual CFO is now -945.15% below its all-time high of $10.56 million, reached on 30 April 2018.KALV Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$40.22 M
-$25.11 M-166.27%
31 July 2024
Summary:
KalVista Pharmaceuticals quarterly cash flow from operations is currently -$40.22 million, with the most recent change of -$25.11 million (-166.27%) on 31 July 2024. Over the past year, it has dropped by -$20.39 million (-102.88%). KALV quarterly CFO is now -242.52% below its all-time high of $28.22 million, reached on 31 January 2018.KALV Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$102.72 M
-$13.49 M-15.12%
31 July 2024
Summary:
KalVista Pharmaceuticals TTM cash flow from operations is currently -$102.72 million, with the most recent change of -$13.49 million (-15.12%) on 31 July 2024. Over the past year, it has dropped by -$24.24 million (-30.89%). KALV TTM CFO is now -722.06% below its all-time high of $16.51 million, reached on 31 January 2018.KALV TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KALV Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -18.6% | -102.9% | -30.9% |
| 3 y3 years | -195.8% | -105.8% | -83.7% |
| 5 y5 years | -145.4% | -414.7% | -153.9% |
KALV Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -195.8% | at low | -333.0% | at low | -83.7% | at low |
| 5 y | 5 years | -195.8% | at low | -1021.0% | at low | -240.5% | at low |
| alltime | all time | -945.1% | at low | -242.5% | at low | -722.1% | at low |
KalVista Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | - | -$40.22 M(+166.3%) | -$102.72 M(+15.1%) |
| Apr 2024 | -$89.23 M(+18.6%) | -$15.11 M(-45.2%) | -$89.23 M(-7.8%) |
| Jan 2024 | - | -$27.57 M(+39.1%) | -$96.76 M(+23.3%) |
| Oct 2023 | - | -$19.82 M(-25.8%) | -$78.48 M(-1.0%) |
| July 2023 | - | -$26.73 M(+18.1%) | -$79.25 M(+5.3%) |
| Apr 2023 | -$75.26 M(-3.7%) | -$22.64 M(+143.7%) | -$75.26 M(-5.2%) |
| Jan 2023 | - | -$9.29 M(-54.9%) | -$79.41 M(-5.7%) |
| Oct 2022 | - | -$20.59 M(-9.4%) | -$84.19 M(+1.3%) |
| July 2022 | - | -$22.74 M(-15.1%) | -$83.14 M(+6.4%) |
| Apr 2022 | - | -$26.79 M(+90.5%) | -$78.13 M(+25.2%) |
| Apr 2022 | -$78.13 M(+159.0%) | - | - |
| Jan 2022 | - | -$14.06 M(-28.0%) | -$62.39 M(+11.6%) |
| Oct 2021 | - | -$19.55 M(+10.2%) | -$55.91 M(+26.2%) |
| July 2021 | - | -$17.73 M(+60.6%) | -$44.32 M(+46.9%) |
| Apr 2021 | -$30.17 M(-32.7%) | -$11.04 M(+45.6%) | -$30.17 M(-5.0%) |
| Jan 2021 | - | -$7.59 M(-4.6%) | -$31.74 M(-14.8%) |
| Oct 2020 | - | -$7.95 M(+121.6%) | -$37.27 M(+0.4%) |
| July 2020 | - | -$3.59 M(-71.6%) | -$37.13 M(-17.2%) |
| Apr 2020 | -$44.82 M(+23.2%) | -$12.62 M(-3.7%) | -$44.82 M(+4.9%) |
| Jan 2020 | - | -$13.11 M(+67.8%) | -$42.71 M(+5.6%) |
| Oct 2019 | - | -$7.81 M(-30.7%) | -$40.46 M(-2.3%) |
| July 2019 | - | -$11.28 M(+7.3%) | -$41.43 M(+13.9%) |
| Apr 2019 | -$36.37 M | -$10.51 M(-3.2%) | -$36.37 M(+14.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jan 2019 | - | -$10.86 M(+23.6%) | -$31.81 M(-537.7%) |
| Oct 2018 | - | -$8.79 M(+41.4%) | $7.27 M(-17.4%) |
| July 2018 | - | -$6.21 M(+4.3%) | $8.79 M(-16.7%) |
| Apr 2018 | $10.56 M(-144.5%) | -$5.96 M(-121.1%) | $10.56 M(-36.1%) |
| Jan 2018 | - | $28.22 M(-488.8%) | $16.51 M(-241.1%) |
| Oct 2017 | - | -$7.26 M(+63.2%) | -$11.71 M(+93.1%) |
| July 2017 | - | -$4.45 M(+175.2%) | -$6.06 M(-68.1%) |
| Apr 2017 | -$23.72 M(+80.3%) | - | - |
| Sept 2016 | - | -$1.62 M(-77.7%) | -$19.03 M(-16.2%) |
| June 2016 | - | -$7.26 M(+42.8%) | -$22.72 M(+3.7%) |
| Apr 2016 | -$13.16 M(-36.9%) | - | - |
| Mar 2016 | - | -$5.08 M(+0.3%) | -$21.90 M(+5.0%) |
| Dec 2015 | -$20.86 M(+227.6%) | -$5.07 M(-4.5%) | -$20.86 M(+3.6%) |
| Sept 2015 | - | -$5.31 M(-17.6%) | -$20.13 M(+11.5%) |
| June 2015 | - | -$6.44 M(+59.1%) | -$18.05 M(+33.2%) |
| Apr 2015 | -$6.37 M(-43.4%) | - | - |
| Mar 2015 | - | -$4.05 M(-6.6%) | -$13.55 M(+20.4%) |
| Dec 2014 | -$11.25 M(+131.6%) | -$4.34 M(+34.5%) | -$11.25 M(+62.7%) |
| Sept 2014 | - | -$3.22 M(+66.4%) | -$6.92 M(+87.3%) |
| June 2014 | - | -$1.94 M(+10.5%) | -$3.69 M(+110.5%) |
| Mar 2014 | - | -$1.75 M | -$1.75 M |
| Dec 2013 | -$4.86 M(+164.7%) | - | - |
| Dec 2012 | -$1.83 M | - | - |
FAQ
- What is KalVista Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals annual CFO year-on-year change?
- What is KalVista Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals quarterly CFO year-on-year change?
- What is KalVista Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals TTM CFO year-on-year change?
What is KalVista Pharmaceuticals annual cash flow from operations?
The current annual CFO of KALV is -$89.23 M
What is the all time high annual CFO for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high annual cash flow from operations is $10.56 M
What is KalVista Pharmaceuticals annual CFO year-on-year change?
Over the past year, KALV annual cash flow from operations has changed by -$13.97 M (-18.56%)
What is KalVista Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of KALV is -$40.22 M
What is the all time high quarterly CFO for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high quarterly cash flow from operations is $28.22 M
What is KalVista Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, KALV quarterly cash flow from operations has changed by -$20.39 M (-102.88%)
What is KalVista Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of KALV is -$102.72 M
What is the all time high TTM CFO for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high TTM cash flow from operations is $16.51 M
What is KalVista Pharmaceuticals TTM CFO year-on-year change?
Over the past year, KALV TTM cash flow from operations has changed by -$24.24 M (-30.89%)